OTCPK:BITK.F

Stock Analysis Report

Executive Summary

Biosign Technologies Inc. develops and sells cloud-based healthcare software products that address the needs in clinic management, home care operations, health monitoring, and virtual care management.

Snowflake

Fundamentals

Weak fundamentals or lack of information.

Risks

  • Biosign Technologies's last earnings update was 1196 days ago.
  • Biosign Technologies is not covered by any analysts.

Share Price & News

How has Biosign Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OTCPK:BITK.F

-1.5%

US Healthcare Services

1.2%

US Market


1 Year Return

n/a

OTCPK:BITK.F

4.8%

US Healthcare Services

1.7%

US Market

No trading data on BITK.F.

No trading data on BITK.F.


Share holder returns

BITK.FIndustryMarket
7 Day0%-1.5%1.2%
30 Day0%-4.8%4.9%
90 Day0%-4.9%3.7%
1 Yearn/a4.9%4.8%3.9%1.7%
3 Yearn/a49.0%48.6%47.2%37.7%
5 Year-100.0%-100.0%46.4%45.5%60.0%42.4%

Price Volatility Vs. Market

How volatile is Biosign Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Biosign Technologies undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether Biosign Technologies is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Biosign Technologies has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of BITK.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Biosign Technologies regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Biosign Technologies expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

28.0%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biosign Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of BITK.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Biosign Technologies's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Biosign Technologies performed over the past 5 years?

0.2%

Historical Healthcare annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Insufficient past earnings data to establish if Biosign Technologies's year on year earnings growth rate was positive over the past 5 years.

Unable to compare Biosign Technologies's 1-year growth to the 5-year average as past earnings data has not been reported.

Unable to compare Biosign Technologies's 1-year growth to the US Healthcare Services industry average as past earnings data has not been reported.


Return on Equity

Unable to establish if Biosign Technologies has efficiently used shareholders’ funds last year as no Return on Equity data is available.


Return on Assets

Unable to establish if Biosign Technologies has efficiently used its assets last year compared to the US Healthcare Services industry average (Return on Assets) as past financial data has not been reported.


Return on Capital Employed

Unable to establish if Biosign Technologies improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to insufficient past data.


Next Steps

Financial Health

How is Biosign Technologies's financial position?


In this section we usually analyse Biosign Technologies's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Biosign Technologies has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of BITK.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Biosign Technologies's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is Biosign Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Biosign Technologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Biosign Technologies's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Biosign Technologies has not reported any payouts.

Unable to verify if Biosign Technologies's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Biosign Technologies has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Biosign Technologies's salary, the management and board of directors tenure and is there insider trading?

5.2yrs

Average management tenure


CEO

Michael Gross 0

4.6yrs

Tenure

0

Dr. Michael Gross, ICD, known as Mike, has been Interim Chief Executive Officer of Biosign Technologies Inc. since August 2014. Dr. Gross serves as Medical Director of QEII Health Sciences at Tissue Bank.  ...


Management Age and Tenure

5.2yrs

Average Tenure

The average tenure for the Biosign Technologies management team is over 5 years, this suggests they are a seasoned and experienced team.


Insider Trading

No 3 month insider trading information.


Management Team

  • Michael Gross

    Chairman & Interim CEO

    • Tenure: 4.6yrs
  • Eva Kettle

    Vice President of Research

    • Tenure: 15yrs
    • Compensation: CA$135.00k
  • John Rizvi

    Managing Director of Middle East & Asia

    • Tenure: 5.2yrs
  • Randy Polley

    Senior Business Development Executive

    • Tenure: 5.2yrs
    • Compensation: CA$83.00k

Board Members

  • Michael Gross

    Chairman & Interim CEO

    • Tenure: 4.6yrs
  • Dennis Rygwalski (71yo)

    Independent Director

    • Tenure: 6yrs

Company Information

Biosign Technologies Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Biosign Technologies Inc.
  • Ticker: BITK.F
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: US$2.282k
  • Shares outstanding: 22.82m
  • Website: https://null

Number of Employees


Location

  • Biosign Technologies Inc.
  • 14-3715 Laird Road
  • Mississauga
  • Ontario
  • L5L 0A3
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BITK.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDMay 2007

Biography

Biosign Technologies Inc. develops and sells cloud-based healthcare software products that address the needs in clinic management, home care operations, health monitoring, and virtual care management. It o ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/03/10 00:09
End of Day Share Price2018/12/10 00:00
Earnings2015/09/30
Annual Earnings2014/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.